BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/20/2026 11:00:23 AM | Browse: 18 | Download: 4
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Gut-liver axis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: Dysbiosis, metabolic mediators, and emerging microbiome-targeted therapies
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shamaela Mashneil, Hamna Salimi, Zaw Myo Aung, Fatma Elsayed, Mohammad Malik and Prakash Gupta |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shamaela Mashneil, Department of Gastroenterology and Hepatology, Milton Keynes University Hospital, Standing Way, Milton Keynes MK6 5LD, United Kingdom. s_mashneil@yahoo.com |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Gut-liver axis; Gut microbiome; Dysbiosis; Intestinal permeability; Bile acids; Farnesoid X receptor; Short-chain fatty acids; Faecal microbiota transplantation |
| Core Tip |
The gut-liver axis is implicated in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH), but much mechanistic evidence is preclinical. Dysbiosis, increased intestinal permeability, altered bile-acid signaling and changes in microbial metabolites (short-chain fatty acids, endogenous ethanol, trimethylamine N-oxide, and indoles) are associated with disease in humans, without proof of causality. Lifestyle change has the strongest clinical support; probiotics, synbiotics, and faecal microbiota transplantation have small, mixed trials; engineered bacteria and bacteriophage therapy are preclinical. No microbial or metabolite biomarker is validated for risk stratification, and the approved MASH drugs resmetirom and semaglutide are not microbiome-targeted. |
| Citation |
Mashneil S, Salimi H, Aung ZM, Elsayed F, Malik M, Gupta P. Gut-liver axis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: Dysbiosis, metabolic mediators, and emerging microbiome-targeted therapies. World J Hepatol 2026; In press
|
| PDF |
128445-in-press.pdf
|
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.